НЕФРОГЕННАЯ АНЕМИЯ: ПРОГРЕСС В ПОНИМАНИИ ПАТОФИЗИОЛОГИИ И ПОТЕНЦИАЛ НОВЫХ ПОДХОДОВ К БЕЗОПАСНОЙ ТЕРАПИИ

Аннотация

Нормоцитарная нормохромная анемия является одним из признаков прогрессирующей хронической болезни почек (ХБП), которая связана главным образом с абсолютным или относительным снижением продукции эритропоэтина и дефицитом железа. С открытием в последнее десятилетие гепсидина — регулятора гомеостаза железа, а также различных факторов и сигнальных путей, регулирующих его метаболизм, мы стали значительно лучше понимать патофизиологию анемии при ХБП. В результате резко активизировались исследования по разработке потенциально новых препаратов, которые могли бы с большей эффективностью и безопасностью лечить почечную анемию. В обзоре изложены современные представления о физиологической и патологической роли железа, а также основных механизмах регуляции его метаболизма в организме человека. Особое внимание уделено гепсидину, играющему ключевую роль в регуляции внеклеточного содержания железа. Кроме того, освещаются вопросы, связанные с риск-профилем имеющихся в настоящее время подходов к терапии анемии при ХБП, а также некоторыми потенциально новыми методами лечения, которые могут стать доступными в ближайшей перспективе.

Об авторах

Список литературы

Beutler E., Hoffbrand A.V., Cook J.D. Iron deficiency and overload. Hematology Am. Soc. Hematol. Educ. Program. 2003; 2003(1): 40-61.

Park C.H., Valore E.V., Waring A.J., Ganz T. Hepcidin, a urinary antimicrobial peptide synthesized in the liver. J. Biol.Chem. 2001; 276(11): 7806-10.

Ramey G., Deschemin J.C., Durel B., Canonne-Hergaux F., Nicolas G., Vaulont S. Hepcidin targets ferroportin for degradation in hepatocytes. Haematologica. 2010; 95(3): 501-4.

De Domenico I., Zhang T.Y., Koening C.L., Branch R.W., London N., Lo E. et al. Hepcidin mediates transcriptional changes that modulate acute cytokine-induced inflammatory responses in mice. J. Clin. Invest. 2010; 120(7): 2395-2405.

Core A.B., Canali S., Babitt J.L. Hemojuvelin and bone morphogenetic protein (BMP) signaling in iron homeostasis. Front Pharmacol. 2014; 5: 104.

Corradini E., Meynard D., Wu Q., Chen S., Ventura P., Pietrangelo A. et al. Serum and liver iron differently regulate the bone morphogenetic protein 6 (BMP6)-SMAD signaling pathway in mice. Hepatology. 2011; 54(1): 273-84.

Bridle K.R., Frazer D.M., Wilkins S.J., Dixon J.L., Purdie D.M., Crawford D.H. et al. Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis. Lancet. 2003; 361(9358): 669-73.

Nemeth E., Rivera S., Gabayan V., Keller V., Taudorf S., Pedersen B.K. et al. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J. Clin. Invest. 2004; 113(9): 1271-6.

Besson-Fournier C., Latour C., Kautz L., Bertrand J., Ganz T., Roth M.P. et al. Induction of activin B by inflammatory stimuli up-regulates expression of the iron-regulatory peptide hepcidin through Smad1/5/8 signaling. Blood. 2012; 120(2): 431-9.

Nicolas G., Chauvet C., Viatte L., Danan J.L., Bigard X., Devaux I. et al. The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation. J. Clin. Invest. 2002; 110(7): 1037-44.

Liu Q., Davidoff O., Niss K., Haase V.H. Hypoxia-inducible factor regulates hepcidin via erythropoietin-induced erythropoiesis. J. Clin. Invest. 2012; 122(12): 4635-44.

Piperno A., Galimberti S., Mariani R., Pelucchi S., Ravasi G., Lombardi C. et al. Modulation of hepcidin production during hypoxia-induced erythropoiesis in humans in vivo: Data from the HIGHCARE project. Blood. 2011; 117(10): 2953-9.

Kautz L., Jung G., Valore E.V., Rivella S., Nemeth E., Ganz T. Identification of erythroferrone as an erythroid regulator of iron metabolism. Nat. Genet. 2014; 46(7): 678-84.

Kautz L., Nemeth E. Molecular liaisons between erythropoiesis and iron metabolism. Blood. 2014; 124(4): 479-82.

Onuma S., Honda H., Kobayashi Y., Yamamoto T., Michihata T., Shibagaki K. et al. Effects of long-term erythropoiesis-stimulating agents on iron metabolism in patients on hemodialysis. Ther. Apher. Dial. 2015; 19(6): 582-9.

Honda H., Kobayashi Y., Onuma S., Shibagaki K., Yuza T., Hirao K. et al. Associations among erythroferrone and biomarkers of erythropoiesis and iron metabolism, and treatment with long-term erythropoiesis-stimulating agents in patients on hemodialysis. PLoS One. 2016; 11(3): e0151601.

McClellan W.M., Flanders W.D., Langston R.D., Jurkovitz C., Presley R. Anemia and renal insufficiency are independent risk factors for death among patients with congestive heart failure admitted to community hospitals: A population-based study. J. Am. Soc. Nephrol. 2002; 13(7): 1928-36.

Astor B.C., Arnett D.K., Brown A., Coresh J. Association of kidney function and hemoglobin with left ventricular morphology among African Americans: The Atherosclerosis Risk in Communities (ARIC) study. Am. J. Kidney Dis. 2004; 43(5): 836-45.

Panwar B., Gutierrez O.M. Disorders of iron metabolism and anemia in chronic kidney disease. Semin Nephrol. 2016; 36(4): 252-61.

Kuragano T., Shimonaka Y., Kida A., Furuta M., Nanami M., Otaki Y. et al. Determinants of hepcidin in patients on maintenance hemodialysis: Role of inflammation. Am. J. Nephrol. 2010; 31(6): 534-40.

Zaritsky J., Young B., Wang H.J., Westerman M., Olbina G., Nemeth E. et al. Hepcidin — a potential novel biomarker for iron status in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2009; 4(6): 1051-6.

Milward E.A., Trinder D., Wilcox C.E., Britton R.S., Ramm G.A., Olynyk J.K. Is HFE involved in increased hepcidin expression and hypoferremia in inflammation and anemia of chronic disease? Hepatology. 2005; 41(4): 936-8.

Eleftheriadis T., Liakopoulos V., Antoniadi G., Kartsios C., Stefanidis I. The role of hepcidin in iron homeostasis and anemia in hemodialysis patients. Semin Dial. 2009; 22(1): 70-7.

Pecoits-Filho R., Lindholm B., Axelsson J., Stenvinkel P. Update on interleukin-6 and its role in chronic renal failure. Nephrol.Dial.Transplant. 2003; 18(6): 1042-5.

Babitt J.L., Lin H.Y. Molecular mechanisms of hepcidin regulation: Implications for the anemia of CKD. Am. J. Kidney Dis. 2010; 55(4): 726-41.

Vos F.E., Schollum J.B., Coulter C.V., Doyle T.C., Duffull S.B., Walker R.J. Red blood cell survival in long-term dialysis patients. Am. J. Kidney Dis. 2011; 58(4): 591-8.

Alon D.B., Chaimovitz C., Dvilansky A., Lugassy G., Douvdevani A., Shany S. et al. Novel role of 1,25(OH)(2)D(3) in induction of erythroid progenitor cell proliferation. Exp. Hematol. 2002; 30(5): 403-9.

Bacchetta J., Zaritsky J.J., Sea J.L., Chun R.F., Lisse T.S., Zavala K. et al. Suppression of iron-regulatory hepcidin by vitamin D. J. Am. Soc. Nephrol. 2014; 25(3): 564-72.

Sazawal S., Black R.E., Ramsan M., Chwaya H.M., Stoltzfus R.J., Dutta A. et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: Community-based, randomised, placebo-controlled trial. Lancet. 2006; 367(9505): 133-43.

Boelaert J.R., Vandecasteele S.J., Appelberg R., Gordeuk V.R. The effect of the host’s iron status on tuberculosis. J. Infect. Dis. 2007; 195(12): 1745-53.

McDermid J.M., Jaye A., Schim van der Loeff M.F., Todd J., Bates C., Austin S. et al. Elevated iron status strongly predicts mortality in West African adults with HIV infection. J. Acqui.r Immune Defic Syndr. 2007; 46(4): 498-507.

Drueke T., Witko-Sarsat V., Massy Z., Descamps-Latscha Z., Guerin A.P., Marchais S.J. et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002; 106(17): 2212-7.

Barany P., Eriksson L.C., Hultcrantz R., Pettersson E., Bergstrom J. Serum ferritin and tissue iron in anemic dialysis patients. Miner Electrolyte Metab. 1997; 23(3-6): 273-6.

Hentze M.W., Muckenthaler M.U., Andrews N.C. Balancing acts: Molecular control of mammalian iron metabolism. Cell. 2004; 117(3): 285-97.

Saeed O., Otsuka F., Polavarapu R., Karmali V., Weiss D., Davis T. et al. Pharmacological suppression of hepcidin increases macrophage cholesterol efflux and reduces foam cell formation and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2012; 32(2): 299-307.

Wilson J.G. Iron and glucose homeostasis: New lessons from hereditary haemochromatosis. Diabetologia. 2006; 49(7): 1459-61.

Stadler N., Lindner R.A., Davies M.J. Direct detection and quantification of transition metal ions in human atherosclerotic plaques: Evidence for the presence of elevated levels of iron and copper. Arterioscler. Thromb. Vasc. Biol. 2004; 24(5): 949-54.

Finn A.V., Nakano M., Polavarapu R., Karmal V., Saeed O., Zhao X. et al. Hemoglobin directs macrophage differentiation and prevents foam cell formation in human atherosclerotic plaques. J. Am. Coll Cardiol. 2012; 59(2): 166-77.

Drueke T.B., Locatelli F., Clyne N., Eckardt K.U., Macdougall I.C., Tsakiris D. et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N. Engl. J. Med. 2006; 355(20): 2071-84.

Singh A.K., Szczech L., Tang K.L., Barnhart H., Sapp S., Wolfson M. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 355(20): 2085-98.

Winkelmayer W.C. Against TREATing all patients alike: Lessons from an FDA advisory committee meeting. J. Am. Soc. Nephrol. 2011; 22(1): 1-2.

Liu Y., Xu Y., Thilo F., Friis U.G., Jensen B.L., Scholze A. et al. Erythropoietin increases expression and function of transient receptor potential canonical 5 channels. Hypertension. 2011; 58(2): 317-24.

Janmaat M.L., Heerkens J.L., de Bruin A.M., Klous A., de Waard V., de Vries C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood. 2010; 115(7): 1453-60.

Hedley B.D., Allan A.L., Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin. Cancer Res. 2011; 17(20): 6373-80.

Hung S.C., Lin Y.P., Tarng D.C. Erythropoiesis-stimulating agents in chronic kidney disease: What have we learned in 25 years? J. Formos Med. Assoc. 2014; 113(1): 3-10.

Freitas J.P., Filipe P.M. Pentoxifylline. A hydroxyl radical scavenger. Biol. Trace Elem. Res. 1995; 47(1-3): 307-11.

Bienvenu J., Doche C., Gutowski M.C., Lenoble M., Lepape A., Perdrix J.P. Production of proinflammatory cytokines and cytokines involved in the TH1/TH2 balance is modulated by pentoxifylline. J. Cardiovasc. Pharmacol. 1995; 25(Suppl. 2): S80-4. PMID:8699868.

Benbernou N., Esnault S., Potron G., Guenounou M. Regulatory effects of pentoxifylline on T-helper cell-derived cytokine production in human blood cells. J. Cardiovasc. Pharmacol. 1995; 25(Suppl. 2): S75-9. (PMID:8699867).

Johnson D.W., Pascoe E.M., Badve S.V., Dalziel K., Cass A., Clarke P. et al. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: The Handling Erythropoietin Resistance with Oxpentifylline (HERO) trial. Am. J. Kidney Dis. 2015; 65(1): 49-57.

Ferrari P., Mallon D., Trinder D., Olynyk J.K. Pentoxifylline improves haemoglobin and interleukin-6 levels in chronic kidney disease. Nephrology (Carlton). 2010; 15(3): 344-9.

Bolignano D., D’Arrigo G., Pisano A., Coppolino G. Pentoxifylline for anemia in chronic kidney disease: A systematic review and meta-analysis. PLoS One. 2015; 10(8): e0134104.

Besarab A., Chernyavskaya E., Motylev I., Shutov E., Kumbar L.M., Gurevich K. et al. Roxadustat (FG-4592): Correction of anemia in incident dialysis patients. J. Am. Soc. Nephrol. 2016; 27(4): 1225-33.

Pergola P.E., Spinowitz B.S., Hartman C.S., Maroni B.J., Haase V.H. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016; 90(5): 1115-22.

Flamme I., Oehme F., Ellinghaus P., Jeske M., Keldenich J., Thuss U. Mimicking hypoxia to treat anemia: HIF-stabilizer BAY 85-3934 (Molidustat) stimulates erythropoietin production without hypertensive effects. PLoS One. 2014; 9(11): e111838.

Holdstock L., Meadowcroft A.M., Maier R., Johnson B.M., Jones D., Rastogi A. et al. Four-week studies of oral hypoxia-inducible factor-prolyl hydroxylase inhibitor GSK1278863 for treatment of anemia. J. Am. Soc. Nephrol. 2016; 27(4): 1234-44.

Maxwell P.H., Eckardt K.U. HIF prolyl hydroxylase inhibitors for the treatment of renal anaemia and beyond. Nat. Rev. Nephrol. 2016; 12(3): 157-68.

Krock B.L., Skuli N., Simon M.C. Hypoxia-induced angiogenesis: Good and evil. Genes Cancer. 2011; 2(12): 1117-33.

Kapitsinou P.P., Rajendran G., Astleford L., Michael M., Schonfeld M.P., Fields T. et al. The endothelial prolyl-4-hydroxylase domain 2/hypoxia-inducible factor 2 axis regulates pulmonary artery pressure in mice. Mol. Cell Biol. 2016; 36(10): 1584-94.

Semenza G.L. Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu. Rev. Pathol. 2014; 9: 47-71.

Cooke K.S., Hinkle B., Salimi-Moosavi H., Foltz I., King C., Rathanaswami P. et al. A fully human anti-hepcidin antibody modulates iron metabolism in both mice and nonhuman primates. Blood. 2013; 122(17): 3054-61.

Moebius U., Feuerer W., Fenzl E., Swelm R., Swinkels D.W., Hohlbaum A. A Phase I Study Investigating the Safety, Tolerability,Pharmacokinetics and Pharmacodynamic activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects. Blood. 2015; 126(23): 536.

Carvalho C., Isakova T., Collerone G., Olbina G., Wolf M., Westerman M. et al. Hepcidin and disordered mineral metabolism in chronic kidney disease. Clin. Nephrol. 2011; 76(2): 90-8.

Icardi A., Paoletti E., De Nicola L., Mazzaferro S., Russo R., Cozzolino M. Renal anaemia and EPO hypo responsiveness associated with vitamin D deficiency: The potential role of inflammation. Nephrol. Dial. Transplant. 2013; 28(7): 1672-9.

Zughaier S.M., Alvarez J.A., Sloan J.H., Konrad R.J., Tangpricha V. The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes. J. Clin.Transl. Endocrinol. 2014; 1(1): e19-e25.

Rivkin M., Simerzin A., Zorde-Khvalevsky E., Chai C., Yuval J.B., Rosenberg N. et al. Inflammation-Induced Expression and Secretion of MicroRNA122 Leads to Reduced Blood Levels of Kidney-Derived Erythropoietin and Anemia. Gastroenterology. 2016; 151: 999-1010.

Ключевые слова